ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ketorolac trometamol, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; disodium edetate; benzalkonium chloride; octoxinol 40; sodium hydroxide; hydrochloric acid; purified water - acular eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic conjunctivitis. acular eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

allergan australia pty ltd - ketorolac trometamol -

मलेशिया - अंग्रेज़ी - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - ketorolac tromethamine -

मलेशिया - अंग्रेज़ी - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

allergan malaysia sdn bhd - ketorolac tromethamine -

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - lucentis is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to choroidal neovascularisation (cnv)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - faricimab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine; acetic acid; methionine; sodium chloride; sucrose; polysorbate 20; water for injections - vabysmo is indicated for the treatment of:,- neovascular (wet) age-related macular degeneration (namd),- diabetic macular oedema (dmo).

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - brolucizumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: water for injections; polysorbate 80; sucrose; sodium citrate - beovu is indicated for the treatment of: ? neovascular (wet) age-related macular degeneration (amd). ? diabetic macular oedema (dme).

इसराइल - अंग्रेज़ी - Ministry of Health

roche pharmaceuticals (israel) ltd - faricimab - solution for injection - faricimab 120 mg/ml - faricimab - vabysmo is a vascular endothelial growth factor (vegf) and angiopoietin 2 (ang-2) inhibitor indicated for the treatment of patients with:• neovascular (wet) age-related macular degeneration (namd) • diabetic macular edema (dme)

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

allergan pharmaceuticals ireland - ketorolac trometamol - eye drops, solution - 0.5 percent weight/volume - antiinflammatory agents, non-steroids; ketorolac

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - ketorolac trometamol - eye drops - 5mg/1ml